Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound doubled in the fourth quarter year over year, despite ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

As the Q4 2024 pharma earnings period rolls on through the first month of President Donald Trump’s second term, executives ...

The UK Chancellor’s messaging at Davos recalled former Taoiseach Enda Kenny’s efforts to extol the recovery of the Irish ...

What's better than a good thing? More of a good thing. Income investors can find plenty of "good things" in the market these ...

The pharmaceutical giant and blue-chip favorite for dividend-focused investors, Pfizer Inc. (NYSE:PFE) fell by 3.5% in a week despite a growth in the sales including Comirnaty, owing to the threat ...

We recently published a list of Why Are These 10 Dividend Stocks Declining? In this article, we are going to take a look at ...

The doctor beamed onto a health clinic video screen in October to convince the regional health board to ban public clinics in ...

Robert F. Kennedy Jr. has been a vocal opponent of the COVID vaccines, particularly from Pfizer Inc. (NYSE:PFE). The Covid vaccines and pills earned Pfizer its peak sales during the pandemic and ...

Down 50% With a 5.9% Dividend Yield, Here's Why This Dirt Cheap Value Stock Is Worth Buying in February Want Decades of Passive Income? 2 Top Dividend Stocks to Buy in 2025 and Hold Forever. Tech ...

Here, we explain the facts behind several more of Robert F. Kennedy Jr.’s claims during his two Senate hearings as nominee ...

As advertisers pay more for an ever-scarcer supply of ratings points, pharma’s ironclad devotion to TV could finally be in ...